A randomized study of 991 newly diagnosed MM patients treated with thalidomide, evaluating the incidence of VTE with low-molecular-weight heparin (enoxaparin 40 mg/d), fixed low-dose warfarin (1.25 mg/d), and aspirin (100 mg/d).²⁸  Patients treated with bortezomib-melphalan-prednisone (no prophylaxis) are shown as controls. P > 0.05 (not significant).